Clinical Trials Logo

Filter by:
NCT ID: NCT02789345 Completed - Clinical trials for Non-small Cell Lung Cancer

A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer

Start date: October 24, 2016
Phase: Phase 1
Study type: Interventional

The main purpose of this study is to evaluate the safety of ramucirumab or necitumumab in combination with osimertinib in participants with non-small cell lung cancer (NSCLC).

NCT ID: NCT02789046 Completed - Clinical trials for Peripheral Venous Catheterization

DIFFICULT INTRAVENOUS ACCESS IN ADULTS (VENSCORE)

VENSCORE
Start date: June 2016
Phase:
Study type: Observational

The objective of the prospective multicenter observational study consists in defining a difficult intravenous access score in adult, during the preoperative period. The main objective: the outcome of interest is defined as failure of cannulation on first attempt. The risk factors of failure of cannulation on first attempt will be described. Adjusted multivariate models will be constructed. A prediction model will be proposed according to the transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD)

NCT ID: NCT02789007 Completed - Healthy Volunteers Clinical Trials

Effects of Parabolic Flight on Spatial Cognition and Hippocampal Plasticity

HypoCampus
Start date: March 2016
Phase: N/A
Study type: Interventional

The main objective of this experiment is to assess the impact of parabolic flight on (1) spatial memory and orientation, (2) the changes in brain structure and function, and particularly the hippocampal formation, and (3) biochemical markers of stress and neuroplasticity. A preliminary study will be performed with the aims (1) to test during weightlessness hardware used to administer visuo-spatial testing and (2) to determine the optimal body posture for testing under microgravity conditions (i.e. body posture for which change in visuo-spatial testing induced by weightlessness is maximal). The main criteria are: - Structural and functional changes of brain evaluated by fMRI; - Cognitive performance, and specifically spatial cognition using a series computer-based tasks. - Key neurotrophins determined in venous blood samples The criteria used in the preliminary experiment is visuo-spatial performance evaluated with a computer-based test assessing spatial cognition. The investigators hypothesize that hippocampal structure and function, and particularly the dentate gyrus, will be altered after parabolic flight compared to ground based controls. Specifically, the 3 tested hypotheses are: - Parabolic flight induces changes in hippocampal structure; - Weightlessness induces changes in cognitive performance, and specifically spatial cognition; - There is a correlation between changes in hippocampal structure and changes in visuo-spatial memory performance. - There is a correlation between changes in hippocampal structure and changes in key neurotrophins. The hypothesis tested during the preliminary experiment is that body posture affects the changes in spatial cognition performance.

NCT ID: NCT02788643 Completed - Lung Cancer Clinical Trials

Study of Collagen IV and XIX in Bronchoalveolar Lavage, Pulmonary Aspiration and Bronchial Biopsies

BRONCOLL
Start date: May 2014
Phase:
Study type: Observational

Collagens are proteins present in all tissues. Besides their structural role, recent data showed that they were able to regulate many cellular functions. Many interactions occur between extracellular matrix macromolecules, especially collagen, and various cell types. These interactions can be controlled by peptides derived extracellular matrix macromolecules, called matrikines. Previous work from the investigators laboratory and others have shown that several C-terminal domain (NC1 domains) from basement membrane-associated collagens could regulate many cellular activities. Lung is an organ particularly abundant in basement membranes. It is likely that various lung diseases may affect metabolism of basement membrane associated collagens. To the investigators knowledge, no study has focused on the expression of collagen XIX α1 chain and collagen IV chains α3 and α4 chains in lung and studied possible variations of expression in various pathophysiological situations. The aim of this study are to: - Study the presence of collagen IV and XIX (or fragments) in different types of sampling such as bronchoalveolar lavage, pulmonary aspiration and bronchial biopsies - Evaluate quantitative variations of expression of these collagen in different pulmonary diseases, especially chronic obstructive bronchopneumopathy, infectious pneumonia, pneumonitis or lung cancer.

NCT ID: NCT02788513 Completed - Alzheimer Disease Clinical Trials

BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.

Start date: August 11, 2016
Phase: Phase 2
Study type: Interventional

The study is designed to compare the effects of BI 425809 compared to placebo in patients with cognitive impairment due to Alzheimer's Disease.

NCT ID: NCT02788474 Completed - Clinical trials for Idiopathic Pulmonary Fibrosis

Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment

Start date: June 9, 2016
Phase: Phase 4
Study type: Interventional

Identifying biomarkers to predict the clinical course and benefits of therapy early in the course of the disease remains one of the most urgent and relevant challenges to improve overall patient management, to prevent treatment delay or overtreatment. This study is conducted to examine the effect of nintedanib treatment on change in biomarkers indicative of extracellular matrix turnover which have been shown recently to correlate with disease progression. This study further aims to confirm the association of biomarker course during the first three months of treatment and disease progression.

NCT ID: NCT02788344 Completed - Clinical trials for Myocardial Infarction

Quality and Safety of Initial Management for ST-segment Elevation Myocardial Infarction

STEMI-Qual
Start date: May 15, 2017
Phase:
Study type: Observational

This is a multicenter multidisciplinary study designed to investigate patient, provider, and system-related factors that are associated with the quality and safety of initial management for suspected ST-segment elevation myocardial infarction (STEMI) evolving for less than 12 hours in daily practice. The primary hypotheses are that delayed reperfusion therapy for suspected STEMI independently relates to provider practice patterns and system barriers. It is further postulated that non-compliance with target delays in implementing percutaneous coronary intervention (PCI) or fibrinolytic therapy is associated with worse in-hospital clinical outcomes. The secondary hypotheses are that the delivery of acute reperfusion therapy within target delays is associated with increased rates of false-positive cardiac catheterization laboratory activation, inadvertent fibrinolytic therapy, and bleeding events. The project will be conducted in three emergency medical services and 23 public and private (for-profit and non-for-profit) acute care hospitals in Northern Alps in France. Data over the index hospital stay period will be retrospectively collected for all the patients included in an ongoing prospective regional hospital-based clinical registry of suspected STEMI from October, 1st, 2002 to December, 31, 2014. Inclusion of 7435 patients is anticipated. In this observational retrospective study, no specific intervention is assigned to participants. All diagnostic testing, procedures, and medication ordering are performed at the discretion of attending physicians. No enrollment or follow-up visits are planned. The primary effectiveness outcome is timely acute reperfusion therapy. The secondary effectiveness outcomes include false-positive cardiac catheterization laboratory activation for catheterization candidates and inadvertent fibrinolytic therapy. The secondary medical outcomes include in-hospital all-cause mortality, major adverse cardiovascular events, and major bleeding events. Multivariable logistic regression model will be developed to identify baseline characteristics that are independently associated with timely acute reperfusion therapy. Propensity score analysis will be performed for comparing clinical outcomes between timely acute reperfusion therapy recipients and non-recipients.

NCT ID: NCT02788331 Completed - Surgical Procedures Clinical Trials

Trends in Volume-Outcome Relationship in Surgery

TREVORS
Start date: April 2016
Phase: N/A
Study type: Observational

The explanatory mechanism of the relationship between the volume of surgical procedures performed by individual hospitals and the occurrence of serious adverse events is not clear. Based on the " practice makes perfect " dogma, we will explore whether a learning effect can explain the volume-outcome relationship for complex surgical procedures using a nationwide dataset. Especially, we assume that increasing volume of procedures over time may be associated with improved outcomes.

NCT ID: NCT02788253 Completed - Clinical trials for Intubation; Difficult

Mallampati Classification vs Best Visible Mallampati for Prediction of Difficult Tracheal Intubation

Start date: June 1, 2017
Phase:
Study type: Observational

Mallampati score (classification of the visibility of oropharyngeal structures) should be performed in the sitting position, head in the neutral position, mouth widely open, and tongue protrudes, without phonation. However, phonation, and position modify the visibility of oropharyngeal structures and thus the Mallampati score. We aimed at evaluating the predictive value of the best observable Mallampati score as compare to the recommended Mallampati score.

NCT ID: NCT02788006 Completed - Clinical trials for Colorectal Adenocarcinoma

Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years With a Metastatic Colorectal Adenocarcinoma .

REGOLD
Start date: January 2016
Phase: Phase 2
Study type: Interventional

Multicenter prospective phase II study evaluating regorafenib in older patients with metastatic colorectal cancer